Mereo Biopharma Sustainability Profile
Mereo Biopharma Group plc, commonly referred to as Mereo Biopharma, is a pioneering biopharmaceutical company headquartered in Great Britain. Founded in 2015, the company focuses on developing innovative therapies for patients with rare diseases and unmet medical needs, particularly in the fields of oncology and metabolic disorders. Mereo Biopharma's core products, including its unique therapeutic candidates, are designed to address significant gaps in current treatment options, showcasing the company's commitment to advancing healthcare. With a strong emphasis on clinical development, Mereo has achieved notable milestones, including successful clinical trials that position it as a key player in the biopharma industry. As it continues to expand its operational reach, Mereo Biopharma is dedicated to delivering transformative solutions that enhance patient outcomes and solidify its market presence.
DitchCarbon Score
How does Mereo Biopharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mereo Biopharma's score of 28 is lower than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Mereo Biopharma's reported carbon emissions
In 2021, Mereo Biopharma reported total emissions of approximately 23,144,000 kg CO2e, which fall under Scope 1 and 2 emissions. This figure represents a decrease from 31,130,000 kg CO2e in 2020, indicating a significant reduction in their carbon footprint. However, no emissions data is available for 2022, and the company has not disclosed any Scope 3 emissions. Mereo Biopharma has not set specific reduction targets or commitments through initiatives such as the Science Based Targets initiative (SBTi) or other climate pledges. The absence of documented reduction initiatives suggests that the company may still be in the early stages of formalising its climate strategy. Overall, while Mereo Biopharma has made strides in reducing its emissions from 2020 to 2021, further transparency and commitment to climate action will be essential for future sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | |
|---|---|---|
| Scope 1 | - | - |
| Scope 2 | - | - |
| Scope 3 | - | - |
How Carbon Intensive is Mereo Biopharma's Industry?
How Carbon Intensive is Mereo Biopharma's Location?
Mereo Biopharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Mereo Biopharma has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
